President Donald Trump has signed an executive order aimed at accelerating research into psychedelic drugs for mental illness, marking a notable shift from his administration's previous stance on controlled substances. This initiative seeks to expand therapeutic options for conditions such as post-traumatic stress disorder (PTSD) and depression, particularly for patients whose conditions persist after standard therapies.
The executive order, signed on Saturday, April 18, 2026, in the Oval Office at the White House, also included the issuance of priority review vouchers to three companies: Compass Pathways, Usona Institute, and Transcend Therapeutics. These vouchers are designed to expedite parts of the Food and Drug Administration (FDA) review process for their psychedelic or MDMA-like therapies. The White House said that psychedelic compounds "show potential in clinical studies to address serious mental illnesses for patients whose conditions persist after completing standard therapy."
For individuals like Marie Phelan, a U.S. Army Reserve veteran deployed to Iraq in 2003, the potential expansion of these therapies is deeply personal. Phelan, who enlisted in 1999, said she had never heard of MDMA before encountering a flyer seeking veterans with PTSD. Her experience with MDMA, she said, "just cracked my heart wide open." Phelan described the treatment as a profound release, stating, "I was carrying this big heavy rucksack and I just put it down on the beach and I started unpacking it one little teeny tiny thing at a time and setting each little thing out on the waves." Phelan is among a small group of Americans who have participated in clinical trials for psychedelic-assisted therapy, finding it transformative for confronting years of trauma in a controlled setting, rather than feeling intoxicated, Phelan said.
Market Reaction and Scientific Debate
Following the announcement, shares of psychedelic drug developers, including Compass Pathways and other companies in the sector, experienced a rally. Wall Street analysts argued that the executive order could help legitimize an industry long perceived as unconventional or fringe. However, the scientific community continues to engage in a robust debate regarding the efficacy and safety of these compounds, raising questions about the industry's long-term growth trajectory.
Research into psychedelics has historically focused on specific conditions. Psilocybin, the active compound in psychedelic mushrooms, has been linked to treating depression, while MDMA-assisted therapy is primarily associated with PTSD, and LSD with anxiety. While psilocybin and ibogaine (a psychoactive compound from a West African shrub) are considered classic psychedelics, MDMA is technically classified as an empathogen. Despite this distinction, researchers and regulators often group MDMA-assisted therapy within the broader psychedelic medicine field due to its use in supervised therapeutic sessions designed to address conditions like PTSD, depression, and addiction.
Brandon Weiss, a researcher at the Center for Psychedelic and Consciousness Research at Johns Hopkins University School of Medicine, emphasized the diversity of these substances. "One of the things that's important to recognize is these are all very different drugs," Weiss said. He further noted, "Psychedelic compounds, they have different safety profiles, different risks," Weiss stated. For instance, ibogaine, which the White House executive order specifically referenced for accelerated research, carries particularly high cardiovascular risks. Unlike psilocybin or MDMA-assisted therapy, ibogaine has not undergone large-scale clinical trials in the United States and has been linked to potentially serious cardiovascular side effects.
Clinical research has shown promising outcomes for some compounds. Late-stage trials sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit advocacy group, indicated that approximately 71% of participants with severe PTSD no longer met the diagnostic criteria for the disorder after MDMA-assisted therapy sessions. Despite these findings, the FDA rejected a previous application for MDMA-assisted therapy in 2024, citing concerns regarding the design of that same late-stage study and the need for additional data. Some psychedelic researchers viewed this decision as evidence of the agency’s continued caution, even amidst mounting public enthusiasm.
Internationally, some countries have already begun to ease restrictions. Australia became the first country to permit authorized psychiatrists to prescribe MDMA and psilocybin for specific mental health conditions in 2023. Researchers in Canada, Switzerland, and the United Kingdom have also expanded clinical studies into psychedelic-assisted therapies.
Challenges and Political Considerations
Weiss said the real worry among some researchers is not that psychedelic therapies are ineffective, but that political momentum could potentially outpace the scientific process. "My biggest concern would be that FDA standards are relaxed for politically motivated reasons," he said, stressing the necessity for more scientific research and an objective interpretation of both risks and benefits.
Kabir Nath, CEO of Compass Pathways, affirmed his company’s commitment to rigorous standards. Nath said his company is adhering to the same FDA standards as all other drugs and would not have advanced its drug, COMP360 Psilocybin, into studies if the data were deemed insufficient, he said. Even proponents of psychedelic treatments acknowledge their complexity, noting that most trials involve extensive preparation with clinicians, supervised treatment sessions, and subsequent integration therapy. These treatments are not without risks, as patients can experience panic attacks, paranoia, elevated heart rates, psychological distress, or overwhelming hallucinations during sessions. In some clinical settings, "rescue drugs" like benzodiazepines or antipsychotic medications are used to calm patients experiencing severe adverse reactions.
Juliana Mercer, executive director of the nonprofit Healing Breakthrough and a U.S. Marine Corps veteran, views the administration’s order as a validation for patients who have long advocated for broader access to alternative mental health treatments. Mercer said that psychedelic-assisted therapy "completely changed" her life after struggling with trauma, providing her with "permission to heal."
The timing of the executive order has also drawn scrutiny. With the Trump administration pursuing VA staffing cuts and deeper military involvement with Iran, some veterans are increasingly questioning the prioritization of their care. Critics suggest the order’s timing could be an attempt to garner veteran support ahead of midterm elections. However, Marie Phelan rejected the idea that backing for psychedelic therapies would automatically translate into political support for President Trump, citing previous cuts to veteran benefits and medical services. "They'd made so many cuts to veteran benefits and medical services," Phelan said. "Great, you did a good thing. You did a right thing… I can't speak for how other people will react, but if that's the intention, I doubt it's effective."
Some industry executives also believe the immediate impact of the executive order might be less significant than headlines suggest. Companies like Compass Pathways were already nearing the final stages of Phase 3 trials before the White House announcement, implying that FDA approval submissions were likely imminent regardless. Nath, CEO of Compass Pathways, said the order primarily signals broader political acceptance of the field, providing "a significant tailwind, encouragement and validation."
